Unlocking Precision Therapeutics With Transformative Diagnostics
Comprehensive molecular diagnostics at the cellular level for precision medicine
DX + AI + TX
Big data diagnostics, AI, and therapeutics working in tandem for patients
Diagnostics
Longitudinal diagnostics with multiomic data captures disease dynamics and biomarkers to transform clinical decision making
Data + AI for target discovery
Analyzing multiomic patient data from all stages leads to disease insights and novel targets
Therapeutics
Immunotherapeutics fueled by our internal discovery pipeline
Our Technology
GenoPredicta Marrow
Our technology performs Whole Genome Sequencing (WGS) on standard bone marrow biopsies, replacing the need for FISH testing and revealing genome-wide insights far beyond the capabilities of probe-based assays or targeted panels
GenoPredicta Blood
Our technology uses WGS on circulating tumor cells from routine blood draws, replacing the need for invasive tissue biopsies and enabling high-resolution longitudinal disease monitoring
GenoPredicta MRD+
The same CTC-based WGS technology behind GenoPredicta Blood also enables detection and monitoring at the single-cell level, to enable MRD applications with unprecedented levels of sensitivity
ImmunoPredicta
Our technology provides multiomic longitudinal snapshots of the immune system that complement our genetic diagnostics to further impact clinical decision making
Growing patient database
The more patient data we collect and analyze, the more powerful our diagnostic and therapeutic discovery tools become.
Therapeutic Targets through AI/ML in patient database
By combining computational and statistical approaches, we analyze genetic and multiomic data from each patient to provide personalized treatment guidance, disease pathways insights, and new therapeutic targets. We focus on identifying the most effective therapy for each individual patient.
Creating LastingImpact—Now and Beyond
Our product portfolio addresses needs across the entire patient journey for hematological malignancies. In the future, we will make our immune profiling technology available for diagnosing and monitoring autoimmune disorders.
Solving core challenges in cancer care
Accurate and In-Depth Tumor Analysis
Our platform leverages comprehensive whole genome sequencing (WGS) of circulating tumor cells (CTCs) from both bone marrow and blood, providing significantly enhanced sensitivity and a wealth of diagnostic information compared to traditional bone marrow FISH assays. This enables more accurate diagnoses and earlier disease intervention, with routine blood monitoring facilitating proactive physician response through timely disease detection.
Immune System Monitoring
Beyond genomic analysis, our technology characterizes multiomic immune system signatures, providing insights to guide personalized therapy selection and optimize patient outcomes.
AI-Powered Therapeutic Discovery
We’re amassing the most comprehensive multiomic database in blood cancer, which we mine using AI to uncover insights into disease biology and potential novel therapies.
The Team
Predicta is guided by a veteran leadership team with decades of commercialization experience across genomics, oncology, and diagnostics.
Francois Aguet, PhD
Head of Computational Biology
Doron Lipson, PhD
CTO
Valentina Nardi, MD
Pathologist
Thomas Mullen, PhD
CLIA Lab Director
Timothy Brennan
Head of Clinical Operations
Danielle Sookiasian
Principal Scientist
Julian Hess
Principal Computational Biologist
Svetlana Podsvirova
Senior Scientist
Geneva Young
Senior Scientist
Molly Hurley
Business Development
The Board
Mara Aspinall
Partner, Illumina Ventures
Jay Wohlgemuth, MD
Independent, Former CMO Quest Diagnostics
Ann DeWitt, PhD
Partner, Engine Ventures
Irene Ghobrial, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
Scientific Co-founders
Predicta was founded by the world’s leading cancer genomics and multiple myeloma researchers from the Broad Institute and Dana Farber Cancer Institute – many are physician scientists who see patients every day.
Kenneth Anderson, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Co-founder of C4 Therapeutics
Irene Ghobrial, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
Gad Getz, PhD
Professor of Pathology, Mass General, Harvard Medical School, Co-founder of the Broad Institute and Scorpion Therapeutics
Keith Flaherty, MD
Professor of Medicine, Mass General, Harvard Medical School, Founder of Loxo Oncology, Strata Oncology, Scorpion Therapeutics
Romanos Sklavenitis-Pistofidis, MD, PhD
Instructor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Predicta is backed by leading life sciences investors
Learn more about GenoPredicta
Thank you
Your submission has been received.